Glutathione protects metastatic melanoma cells against oxidative stress in the murine hepatic microvasculature

Miren J. Anasagasti, Javier J. Martin, Lorea Mendoza, Elena Obrador, Jose M. Estrela, Robert S. McCuskey, Fernando Vidal‐Vanaclocha – 30 December 2003 – Calcein‐labeled B16 melanoma (B16M) cells were injected intraportally, and in vivo video microscopy was used to study the distribution and damage of cancer cells arrested in the liver microvasculature over a period of 4 hours.

Positive T lymphocytotoxic cross‐match in living donor liver transplantation

Yasuhiko Sugawara, Masatoshi Makuuchi, Junichi Kaneko, Yoji Kishi, Shojiro Hata, Norihiro Kokudo – 30 December 2003 – The influence of lymphocytotoxic cross‐match on survival or acute rejection in living donor liver transplantation (LDLT) has not been well examined. We analyzed 133 consecutive adult LDLT cases and assessed patient survival and acute rejection rates. Patients with a positive T lymphocytotoxic cross‐match (n = 12) had a significantly higher chance of rejection within 6 weeks of LDLT (67% versus 28%, P < .001).

Endothelin‐A receptor antagonist reduces microcirculatory disturbances and transplant dysfunction after partial liver transplantation

Daniel Palmes, Tymotheus B. Budny, Udo Stratmann, Hermann Herbst, Hans‐Ullrich Spiegel – 30 December 2003 – Endothelin‐1 can induce microcirculatory disorders by mediating sinusoidal vasoconstriction, lowering the perfusion rate and promoting leukocyte adhesion, all of which may play a role in the pathogenesis of the damage sustained by partial liver transplants. In this pilot study, we investigated a selective endothelin‐A receptor antagonist (Darusentan; Knoll GmbH, Ludwigshafen, Germany) for its potential influence on the microcirculation in the setting of partial liver transplantation.

Surgical treatment of Budd‐Chiari syndrome

Andrew S. Klein, Ernesto P. Molmenti – 30 December 2003 – Shunting and transplantation are satisfactory methods of treating Budd‐Chiari syndrome (BCS). Selection of treatment is based on the degree of hepatic injury (clinical settings), liver biopsy results, potential for parenchymal recovery, and pressure measurements. Shunting is recommended in cases of preserved hepatic function and architecture.

Relationship between portal venous flow and liver regeneration in patients after living donor right‐lobe liver transplantation

Susumu Eguchi, Katsuhiko Yanaga, Nozomu Sugiyama, Sadayuki Okudaira, Junichiro Furui, Takashi Kanematsu – 30 December 2003 – The purpose of this study is to evaluate the relationship between portal venous (PV) velocity and degree of liver regeneration in humans after living donor liver transplantation (LDLT). Between July 1997 and September 2002, a total of 15 adult‐to‐adult LDLTs with right‐lobe grafts were performed, and 13 of these patients were enrolled in this study.

Acquired (non‐Wilsonian) hepatocerebral degeneration: Complex management decisions

Eelco F.M. Wijdicks, Russell H. Wiesner – 30 December 2003 – Portal systemic encephalopathy, in its many guises, can be reversible after medical management or liver transplantation. It is much less certain whether patients with a longstanding neurodegenerative syndrome (known in the medical vernacular as acquired hepatocerebral degeneration) can improve.

Subscribe to